TAILIEUCHUNG - Obesity guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children

Resource use was routinely collected as part of the study. Non-inpatient resource use data was collected using a questionnaire distributed between January 1996 and September 1997. The incremental costs reported in the analysis have the study protocol driven costs removed. These were replaced with a pattern of clinic visits reflecting general practitioner and specialist clinical opinion on the implementation of intensive policy. Where a patient was still alive at the end of the follow-up, a simulation model was used to estimate the time from end of follow-up to death. It was assumed that there would be no continuation of benefit of therapy beyond the trial period in. | Issue date December 2006 NHS National Institute for Health and Clinical Excellence Obesity guidance on the prevention identification assessment and management of overweight and obesity in adults and children Sibutramine Reductil marketing authorisation suspended On 21 January 2010 the MHRA announced the suspension of the marketing authorisation for the obesity drug sibutramine Reductil . This follows a review by the European Medicines Agency which found that the cardiovascular risks of sibutramine outweigh its benefits. Emerging evidence suggests that there is an increased risk of non-fatal heart attacks and strokes with this medicine. The MHRA advises that Prescribers should not issue any new prescriptions for sibutramine Reductil and should review the treatment of patients taking the drug. Pharmacists should stop dispensing Reductil and should advise patients to make an appointment to see their doctor at the next convenient time. People who are currently taking Reductil should make a routine appointment with their doctor to discuss alternative measures to lose weight including use of diet and exercise regimens. Patients may stop treatment before their appointment if they wish. NICE clinical guideline 43 recommended sibutramine for the treatment of obesity in certain circumstances. These recommendations have now been withdrawn and healthcare professionals should follow the MHRA advice. NICE clinical guideline 43 Developed by the National Collaborating Centre for Primary Care and the Centre for Public Health Excellence at NICE NICE clinical guideline 43 Obesity guidance on the prevention identification assessment and management of overweight and obesity in adults and children Ordering information You can download the following documents from CG043 The NICE guideline this document - all the recommendations. Two quick reference guides - summaries of the recommendations for professionals - quick reference guide 1 for local authorities schools and early

• Sức khỏe trẻ em
• certifications levels
• Building Investment
• Pediatric Cardiology
• Renal and Cardiovascular
• Pediatric Cardiac Surgery
• Skill and Creativity